spacer
home > ebr > autumn 2009 > nanotechnology: past, present and future
PUBLICATIONS
European Biopharmaceutical Review

Nanotechnology: Past, Present and Future

 

Over the past 30 years, nanotechnology has shown great promise in advancing the fields of medicine, cosmetics, electronics, material sciences, information technology, energy production and engineering. During this time, public and private funding in the area of nanotechnology has increased to advance the science and commercialisation of nanotechnology-based products. For example, the US National Nanotechnology Initiative’s (NNI) 2010 budget is expected to reach $1.64 billion to support basic research, infrastructure development and technology transfer in the fields of healthcare, electronics, aeronautics, agriculture, food and energy. From this proposed budget, $326 million has been allocated to the National Institutes of Health (NIH) to conduct nanotechnologyrelated medical research (1). According to the Woodrow Wilson International Center for Scholars Project on Emerging Nanotechnologies (PEN), over 800 nanotechnology-based consumer products are currently on the market, with a total value of $147 billion (2). The analysis firm Lux Research predicts that nanotechnology products will reach a total value of $3.1 trillion by 2015. Similar trends are also predicted for nanotechnology-based drug products, whose total market value may reach $200 billion by 2015 (3). It is expected that nanotechnology-based products will continue to be developed as novel and effective therapies move from the bench to the clinic.

NANOTECHNOLOGY: TODAY

The concept of nanotechnology in targeted therapy was first introduced by Paul Ehrlich, the 1908 Nobel Laureate. Ehrlich conceived the notion of ‘magic bullets’: specific compounds that seek out the disease causing organism and destroy it without harming other parts of the body. This is the promise that today’s nanotechnology drug products offer for diagnosing, imaging and treating diseases. The US NNI defines nanotechnology as: “The understanding and control of matter at dimensions between approximately one and 100 nanometers where unique phenomena enable novel applications” (4).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Nakissa Sadrieh obtained her doctorate in Toxicology in 1993 from Rutgers University in New Jersey. Following a postdoctoral fellowship in the Laboratory of Chemical Carcinogenesis at the National Cancer Institute, Nakissa joined the Food and Drug Administration (FDA) in 1996. She is currently the Associate Director for Research Policy and Implementation in the Office of Pharmaceutical Science within the Center for Drug Evaluation and Research (CDER). Her work is aimed at filling research needs to help address regulatory questions. 

Dr Banu Zolnik is a pharmacologist in the Science and Research Staff of the Office of Pharmaceutical Science within CDER, FDA. Prior to joining the FDA in 2008, Banu worked as a postdoctoral fellow in the Nanotechnology Characterization Laboratory at the National Cancer Institute. Banu obtained her doctorate in Pharmaceutical Sciences from the University of Connecticut in 2005. She received her Bachelor of Science in Pharmacy from Istanbul University in Turkey in 1997. Her research interests are related to regulatory aspects of the development of novel dosage drug delivery systems, such as nanoparticles, microspheres, emulsions and liposomes.

spacer
Nakissa Sadrieh
spacer
spacer
spacer
Banu Zolnik
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PPMA Group Industry Awards 2019

PPMA Group is today issuing a ‘Final Call for Entries’ to the 2019 PPMA Group Industry Awards. All companies within the packaging and processing sector are invited to submit their FREE submission by the deadline of 17 July 2019.
More info >>

White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement